Johnson & JohnsonJNJ

JNJ current price
$157.25+1.28%

Capital at risk.

1W
+3.14%
1M
+8.55%
3M
+1.70%
6M
-0.65%
1Y
+1.28%
MAX
+103.82%
About Johnson & Johnson
Ticker
info
JNJ
Trading on
info
NYSE
ISIN
info
US4781601046
Industry
info
Drug Manufacturers - General
Sector
info
Healthcare
CEO
info
Joaquin Duato
Headquarters
info
One Johnson & Johnson Plaza, New Brunswick, NJ, United States, 08933
Employees
info
0
Website
info
jnj.com
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Metrics
BasicAdvanced
Market cap
info
$379B
P/E ratio
info
27.16
EPS
info
$5.79
Dividend Yield
info
3.35%
Beta
info
0.52
Forward P/E ratio
info
14.86
EBIDTA
info
$30.1B
Ex dividend date
info
2025-02-18
Price & volume
Market cap
info
$379B
Average daily volume
info
9.3M
90-day return
info
1.70%
30-day return
info
8.55%
7-day return
info
3.14%
Dividends
Dividend per share
info
$0.00
Dividend yield
info
3.35%
Forward dividend per share
info
$4.96
Forward dividend yield
info
3.35%
Payout ratio
info
49.65%
Valuation
P/E ratio
info
27.16
Forward P/E
info
14.86
PEG ratio
info
1
Trailing P/E
info
27.16
Price to sales
info
4.32
Price to book
info
5.4
Earnings
EPS
info
$5.79
EPS estimate (current quarter)
info
$2.21
EPS estimate (next quarter)
info
$2.14
EBITDA
info
$30.1B
Revenues (TTM)
info
$87.7B
Revenues per share (TTM)
info
$36.43
Technicals
Beta
info
0.52
52-week High
info
$167.51
52-week Low
info
$139.79
50-day moving average
info
$148.25
200-day moving average
info
$154.02
Short ratio
info
1.94
Short %
info
0.68%
Management effectiveness
ROE (TTM)
info
20.89%
ROA (TTM)
info
8.40%
Profit margin
info
16.74%
Gross profit margin
info
$60.9B
Operating margin
info
24.52%
Growth
Quarterly earnings growth (YoY)
info
89.10%
Quarterly revenue growth (YoY)
info
5.20%
Share stats
Outstanding Shares
info
2.41B
Float
info
2.4B
Insiders %
info
0.06%
Institutions %
info
73.25%
Analyst Insights & forecasts
info

44% Buy

56% Hold

0% Sell

Based on information from 23 analysts.

Average price target

info
$168.64
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
$2.29
$2.28
0.44%
Q4 • 23Beat
$2.71
$2.64
2.65%
Q1 • 24Beat
$2.82
$2.70
4.44%
Q2 • 24Beat
$2.42
$2.21
9.50%
Q3 • 24Beat
$2.04
$2.01
1.38%
Q4 • 24Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$22.4B
$4.69B
20.88%
Q2 • 24
$22.5B
$2.69B
11.99%
Q3 • 24
0.11%
42.51%
42.57%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$181B
$110B
60.50%
Q2 • 24
$178B
$108B
60.65%
Q3 • 24
1.55%
1.30%
0.25%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$5.63B
$-13.7B
$7.54B
$4.66B
Q2 • 24
$7.99B
$-3.13B
$-9.88B
$5.71B
Q3 • 24
41.90%
77.15%
230.99%
22.70%
QoQ growth
QuarterlyAnnual
Sentiment analysis

-1.5

Greed

+1.5

0.53

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Johnson & Johnson share?
Collapse

Johnson & Johnson shares are currently traded for $157.25 per share.

How many shares does Johnson & Johnson have?
Collapse

Johnson & Johnson currently has 2.41B shares.

Does Johnson & Johnson pay dividends?
Collapse

No, Johnson & Johnson doesn't pay dividends.

What is Johnson & Johnson 52 week high?
Collapse

Johnson & Johnson 52 week high is $167.51.

What is Johnson & Johnson 52 week low?
Collapse

Johnson & Johnson 52 week low is $139.79.

What is the 200-day moving average of Johnson & Johnson?
Collapse

Johnson & Johnson 200-day moving average is $154.02.

Who is Johnson & Johnson CEO?
Collapse

The CEO of Johnson & Johnson is Joaquin Duato.

How many employees Johnson & Johnson has?
Collapse

Johnson & Johnson has 0 employees.

What is the market cap of Johnson & Johnson?
Collapse

The market cap of Johnson & Johnson is $379B.

What is the P/E of Johnson & Johnson?
Collapse

The current P/E of Johnson & Johnson is 27.16.

What is the EPS of Johnson & Johnson?
Collapse

The EPS of Johnson & Johnson is $5.79.

What is the PEG Ratio of Johnson & Johnson?
Collapse

The PEG Ration of Johnson & Johnson is 1.

What do analysts say about Johnson & Johnson?
Collapse

According to the analysts Johnson & Johnson is considered a hold.

Johnson & Johnson news
thumbs_up_down
Neutral
New nipocalimab data published in mAbs journal details differentiated molecular design, clinical profile and potential of nipocalimab to treat IgG-driven alloantibody and autoantibody diseases

Published results reinforce the high-affinity binding and immunoselective properties of nipocalimab, which has been shown to reduce IgG levels by >75%, including autoantibodies, potentially without affecting other immune functions SPRING HOUSE, Pa. , Feb. 13, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the publication of data detailing the differentiated molecular properties of nipocalimab, an investigational neonatal Fc receptor (FcRn) blocker, in mAbs .a This publication highlights the selective, targeted and high-affinity binding properties of nipocalimab which support its differentiated potential as a treatment option for immunoglobulin G (IgG)-driven alloantibody and autoantibody diseases.1 Nipocalimab is a fully human IgG-1 monoclonal antibody that binds to FcRn, resulting in the reduction of circulating IgG levels including pathogenic IgG autoantibodies.1 The studies established that nipocalimab binds both specifically and with high, pH-independent affinity to FcRn.1 These preclinical studies also established the relationship between FcRn binding and the inhibition of IgG recycling, revealing that nipocalimab achieves time and dose-dependent IgG reductions of greater than 75% without affecting IgG production and without detectable effects on other adaptive and innate immune functions.1 The pH-independent nature of the binding, also noted in this publication, is one factor contributing to the ability to investigate nipocalimab in alloimmune diseases of pregnancy.1 The mechanism of action of nipocalimab was assessed through in vitro and in vivo studies, and attributes noted in the publication are consistent with clinical Phase 1, 2 and 3 studies of nipocalimab.1 The clinical significance is not yet known.

PRNewsWire13 Feb 2025, 13:05